Innovation & Devices
Deramiocel for Duchenne Muscular Dystrophy: FDA Review Raises Questions About Cardiac Benefit
FDA advisers examined whether deramiocel’s cardiac and upper-limb findings outweigh uncertainties in the evidence and risks of repeated cell infusions for Duchenne muscular dystrophy.
Dr. Abu Bakar · August 30, 2026 · 7 min